Lexeo Therapeutics (LXEO) Non-Current Assets (2022 - 2026)

Lexeo Therapeutics' Non-Current Assets history runs 5 years deep, the most recent figure standing at $49.5 million for Q1 2026.

• In Q1 2026, Non-Current Assets rose 142.43% year-over-year to $49.5 million; the TTM figure through Mar 2026 stood at $181.8 million (up 157.93% YoY), while the FY2025 annual figure was $80.3 million, up 285.65% from the prior year.
• Non-Current Assets came in at $49.5 million for Q1 2026 at Lexeo Therapeutics, down from $80.3 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $80.3 million in Q4 2025 to a low of $14.4 million in Q3 2024.
• A 5-year average of $26.3 million and a median of $16.5 million in 2022 frame the typical range for Non-Current Assets.
• Across the five-year window, Non-Current Assets slipped 9.1% in 2024 and soared 285.65% in 2025, its largest moves.
• Lexeo Therapeutics' Non-Current Assets stood at $17.0 million in 2022, then retreated by 8.9% to $15.5 million in 2023, then jumped by 34.22% to $20.8 million in 2024, then jumped by 285.65% to $80.3 million in 2025, then tumbled by 38.36% to $49.5 million in 2026.
• According to Business Quant data, Non-Current Assets over the past three periods registered $49.5 million, $80.3 million, and $16.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison